A Phase II dose-escalation study of sorafenib was conducted in 44 evaluable patients, 19 of whom received prior therapy. [82] The initial dosage was 400 mg twice daily for 28 days, followed by 600 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback